Gemin X Biotechnologies was established in late 1998, in Montréal, Québec as a spin-out of McGill University. The company completed a second round funding in May 2001. Gemin X Biotechnologies seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. The company's mission is to develop integrated capabilities in target discovery and validation, high-throughput screening, medicinal chemistry and preclinical development form the core of the company's discovery engine.
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Latest News
To view this information, you must subscribe to Partneringtools.
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
To view this information, you must subscribe to Partneringtools.
Regional and subsidiary offices
To view this information, you must subscribe to Partneringtools.